Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 921: Which drug is not used in chloroquine-resistant malaria?

A. Sulfadoxine–pyrimethamine
B. Fluoroquinolones (Correct Answer)
C. Quinine
D. Artemisinins

Explanation: **Explanation:** The management of chloroquine-resistant *Plasmodium falciparum* requires switching to drugs with different mechanisms of action or those that bypass the resistance mechanisms (such as the *pfcrt* gene mutation) [2]. **Why Fluoroquinolones are the correct answer:** While some fluoroquinolones (like Ciprofloxacin or Levofloxacin) exhibit weak anti-plasmodial activity *in vitro*, they are **not** clinically used or recommended for the treatment of malaria. Their efficacy is insufficient to achieve clinical cure, and they are primarily reserved for bacterial infections. Using them for malaria would lead to sub-therapeutic dosing and promote bacterial resistance. **Analysis of Incorrect Options:** * **Sulfadoxine–Pyrimethamine (SP):** This antifolate combination was historically the first-line alternative to chloroquine [3]. While resistance to SP is now widespread [4], it is still used in specific regions and as part of Intermittent Preventive Treatment in pregnancy (IPTp). * **Quinine:** For decades, Quinine remained the mainstay for chloroquine-resistant malaria, especially severe cases [3]. It is still used in specific scenarios (e.g., first trimester of pregnancy) or when artemisinins are unavailable. * **Artemisinins:** These are the current "gold standard." Artemisinin-based Combination Therapy (ACT) is the first-line treatment for uncomplicated chloroquine-resistant *P. falciparum* worldwide due to their rapid schizonticidal action [4]. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC)** for Chloroquine-resistant malaria: **ACT** (e.g., Artesunate + Lumefantrine). * **DOC for Severe Malaria:** Intravenous **Artesunate** (preferred over Quinine). * **Mechanism of Chloroquine Resistance:** Mutation in the **pfcrt** (P. falciparum chloroquine resistance transporter) gene, which increases the efflux of the drug from the parasite's food vacuole [2]. * **Antibiotics used in Malaria:** Doxycycline and Clindamycin are used as adjuncts to Quinine [1], but Fluoroquinolones are not.

Question 922: Which drug inhibits the enzyme folate synthase?

A. Sulfonamide (Correct Answer)
B. Clindamycin
C. Rifampicin
D. Norfloxacin

Explanation: ### Explanation **Correct Option: A. Sulfonamide** Sulfonamides are structural analogs of **Para-Amino Benzoic Acid (PABA)**. They act as competitive inhibitors of the enzyme **Dihydropteroate Synthase** (often referred to broadly as folate synthase). In the bacterial folic acid synthesis pathway, this enzyme is responsible for condensing PABA with pteridine to form dihydropteroic acid. Since bacteria must synthesize their own folate (unlike humans who absorb it from diet), this inhibition leads to a deficiency of tetrahydrofolate, halting DNA synthesis and resulting in a **bacteriostatic** effect. **Incorrect Options:** * **B. Clindamycin:** This is a Lincosamide that inhibits protein synthesis by binding to the **50S ribosomal subunit**, specifically interfering with transpeptidation. * **C. Rifampicin:** This drug inhibits **DNA-dependent RNA polymerase**, thereby blocking bacterial transcription (mRNA synthesis). It is a cornerstone of anti-tubercular therapy. * **D. Norfloxacin:** This is a Fluoroquinolone that inhibits **DNA Gyrase (Topoisomerase II)** and Topoisomerase IV, preventing DNA supercoiling and replication. **NEET-PG High-Yield Pearls:** * **Sequential Blockade:** Trimethoprim inhibits the next step in the pathway (**Dihydrofolate Reductase**). Combining a Sulfonamide with Trimethoprim (e.g., Cotrimoxazole) results in synergistic bactericidal action. * **Resistance Mechanism:** Bacteria most commonly develop resistance to sulfonamides by increasing PABA production or mutating the dihydropteroate synthase enzyme. * **Adverse Effects:** Watch for **Stevens-Johnson Syndrome (SJS)**, Kernicterus in newborns, and crystalluria (prevented by alkalinizing urine).

Question 923: What is the DOC for management of visceral Leishmaniasis?

A. Parenteral Sodium stibogluconate
B. Liposomal Amphotericin B (Correct Answer)
C. Miltefosine
D. Pentamidine

Explanation: **Liposomal Amphotericin B** is currently the **Drug of Choice (DOC)** for Visceral Leishmaniasis (Kala-azar), especially in the Indian subcontinent [1]. The underlying medical concept relies on its superior efficacy (cure rates >95%) [1] and significantly lower toxicity compared to conventional agents. The liposomal formulation allows the drug to be specifically taken up by the **reticuloendothelial system (macrophages)** in the liver and spleen—the exact site where *Leishmania donovani* resides—thereby increasing therapeutic index and reducing nephrotoxicity. **Analysis of Incorrect Options:** * **Parenteral Sodium Stibogluconate (SSG):** Formerly the first-line treatment, it is no longer the DOC due to widespread **antimonial resistance** (especially in Bihar, India) [2] and severe side effects like cardiotoxicity and pancreatitis. * **Miltefosine:** This is the first **effective oral drug** for Kala-azar [2]. While highly useful for mass treatment, it is not the primary DOC due to teratogenicity (requires strict contraception) and increasing reports of treatment failure. * **Pentamidine:** Previously used as a second-line agent, it is now rarely used for Leishmaniasis due to significant toxicities, including irreversible diabetes mellitus and hypotension. **High-Yield Clinical Pearls for NEET-PG:** * **WHO Protocol:** A single dose of Liposomal Amphotericin B (10 mg/kg) is the preferred regimen in India. * **Post-Kala-azar Dermal Leishmaniasis (PKDL):** The DOC is also Miltefosine (for 12 weeks) or Amphotericin B. * **Mechanism of Amphotericin B:** It binds to **ergosterol** in the fungal/protozoal cell membrane, creating pores that lead to ion leakage and cell death.

Question 924: How can aminoglycoside toxicity be decreased?

A. Administering the total daily dose once a day (Correct Answer)
B. Administering the total daily dose twice a day
C. Administering a low dose once a day
D. Administering a low dose twice a day

Explanation: ### Explanation The correct answer is **A. Administering the total daily dose once a day.** This approach is based on two key pharmacokinetic and pharmacodynamic properties of aminoglycosides: 1. **Concentration-Dependent Killing:** Aminoglycosides are more effective when peak plasma concentrations ($C_{max}$) are high relative to the Minimum Inhibitory Concentration (MIC). A single large dose achieves a higher peak than multiple smaller doses. 2. **Post-Antibiotic Effect (PAE):** These drugs continue to suppress bacterial growth even after plasma levels fall below the MIC. This allows for a "drug-free interval" without losing efficacy. 3. **Saturable Uptake (Toxicity Mitigation):** Aminoglycoside toxicity (nephrotoxicity and ototoxicity) depends on the **duration of exposure** rather than the peak concentration. The uptake of the drug into the renal cortex and inner ear is a saturable process. By giving the dose once daily, the plasma level remains below the threshold for toxicity for a longer period, allowing the drug to wash out of these tissues, thereby reducing the risk of accumulation. **Analysis of Incorrect Options:** * **Options B & D:** Multiple daily dosing (twice or thrice daily) maintains higher "trough" levels. This constant exposure prevents the renal and vestibular cells from clearing the drug, leading to increased accumulation and higher toxicity. * **Option C:** Administering a low dose once a day would result in sub-therapeutic levels, failing to achieve the required $C_{max}/MIC$ ratio for effective bacterial killing, leading to treatment failure and potential resistance. **High-Yield Clinical Pearls for NEET-PG:** * **Nephrotoxicity:** Usually reversible; manifests as acute tubular necrosis (ATN). * **Ototoxicity:** Often irreversible; can be vestibular (streptomycin, gentamicin) or cochlear (amikacin, neomycin). * **Neuromuscular Blockade:** A rare but serious side effect; treated with **Calcium gluconate** or Neostigmine. * **Monitoring:** Once-daily dosing is also known as "Extended Interval Dosing." It is generally avoided in patients with significant renal impairment or pregnancy.

Question 925: Which of the following drugs is likely to damage the eighth cranial nerve when administered for a long period of time?

A. Ethambutol
B. Isoniazid
C. Rifampicin
D. Streptomycin (Correct Answer)

Explanation: **Explanation:** The correct answer is **Streptomycin**. Streptomycin is an **Aminoglycoside** antibiotic used as a first-line drug in the treatment of Tuberculosis. **1. Why Streptomycin is correct:** Aminoglycosides are notorious for their **ototoxicity** and nephrotoxicity. They accumulate in the endolymph and perilymph of the inner ear, leading to the destruction of sensory hair cells. Specifically, Streptomycin is more **vestibulotoxic** than cochleotoxic, causing symptoms like vertigo, tinnitus, and loss of equilibrium due to damage to the **eighth cranial nerve (Vestibulocochlear nerve)**. **2. Why other options are incorrect:** * **Ethambutol:** Its primary dose-related toxicity is **Optic Neuritis** (damage to the second cranial nerve), leading to decreased visual acuity and red-green color blindness. * **Isoniazid (INH):** The hallmark side effect is **Peripheral Neuropathy** (due to Vitamin B6 deficiency) and hepatotoxicity. It does not typically affect the cranial nerves. * **Rifampicin:** Known for causing **orange-colored secretions** (urine, sweat, tears) and hepatotoxicity. It is a potent microsomal enzyme inducer but is not ototoxic. **NEET-PG High-Yield Pearls:** * **Mnemonic for Aminoglycoside Ototoxicity:** **S**treptomycin and **G**entamicin are primarily **Vestibulotoxic** (S-G-V), while **A**mikacin and **N**eomycin are primarily **Cochleotoxic** (A-N-C). * Streptomycin is contraindicated in pregnancy as it can cause **fetal ototoxicity** (congenital deafness). * Always monitor renal function (Creatinine) when using aminoglycosides, as nephrotoxicity often precedes or exacerbates ototoxicity.

Question 926: Nephrolithiasis occurs with the toxicity to which of the following drugs?

A. Ritonavir
B. Saquinavir
C. Indinavir (Correct Answer)
D. Nalfinavir

Explanation: ### Explanation **Correct Answer: C. Indinavir** **Mechanism and Pathophysiology:** Indinavir is a Protease Inhibitor (PI) used in the treatment of HIV. The primary reason for nephrolithiasis (kidney stones) with Indinavir is its **poor solubility** in urine. Approximately 20% of the drug is excreted unchanged in the urine. At physiological urinary pH, Indinavir tends to crystallize, leading to the formation of radiolucent stones. This can manifest clinically as renal colic, hematuria, or crystalluria. To mitigate this risk, patients are strictly advised to maintain high fluid intake (at least 1.5 to 2 liters of water daily). **Analysis of Incorrect Options:** * **A. Ritonavir:** While a potent PI, it is primarily known for its role as a "pharmacokinetic booster" (inhibiting CYP3A4) and its side effects of GI distress and perioral paresthesia, rather than nephrolithiasis. * **B. Saquinavir:** This was the first PI developed. Its main adverse effects include GI upset and QT interval prolongation, but it is not associated with renal stone formation. * **D. Nelfinavir:** This drug is unique among PIs as it cannot be boosted by Ritonavir. Its most characteristic side effect is significant diarrhea, not nephrolithiasis. **High-Yield Clinical Pearls for NEET-PG:** * **Indinavir "Signature" Side Effects:** Nephrolithiasis and Hyperbilirubinemia (indirect/unconjugated). * **Protease Inhibitor Class Effects:** Metabolic syndrome (dyslipidemia, insulin resistance/hyperglycemia) and Lipodystrophy (buffalo hump/central obesity). * **Other drugs causing Nephrolithiasis:** Acetazolamide, Sulfonamides, and Triamterene. * **Management:** Indinavir-induced stones are often managed with hydration and temporary drug discontinuation; they are typically not visible on standard X-rays (radiolucent).

Question 927: All are true about Cotrimoxazole, except?

A. Resistance is delayed due to drugs in combination
B. Trimethoprim : Sulphamethoxazole ratio is 1:5
C. Similar pharmacokinetics for both components
D. Trimethoprim increases absorption of Sulphamethoxazole (Correct Answer)

Explanation: **Explanation:** **Cotrimoxazole** is a fixed-dose combination of **Trimethoprim (TMP)** and **Sulphamethoxazole (SMZ)**. The correct answer is **Option D** because Trimethoprim does not influence the absorption of Sulphamethoxazole; their combination is based on synergistic pharmacodynamics, not pharmacokinetic enhancement. **Analysis of Options:** * **Option D (Correct):** There is no pharmacokinetic interaction regarding absorption between the two drugs. They are combined because they produce a **sequential blockade** of folate synthesis, converting bacteriostatic action into bactericidal action. * **Option A:** Using two drugs that act on the same metabolic pathway (folic acid synthesis) significantly **delays the development of bacterial resistance**, as the organism would need to develop two simultaneous mutations to bypass the blockade. * **Option B:** The standard preparation contains TMP and SMZ in a **1:5 ratio** (e.g., 80 mg TMP + 400 mg SMZ). This ratio is designed to achieve a steady-state **plasma concentration ratio of 1:20**, which is the optimal MIC (Minimum Inhibitory Concentration) for most susceptible organisms. * **Option C:** Both drugs have **similar pharmacokinetic profiles**: they are well-absorbed orally, have similar half-lives (~10 hours), and comparable volumes of distribution, allowing for synchronized dosing intervals. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** SMZ inhibits *Dihydropteroate synthase*; TMP inhibits *Dihydrofolate reductase*. * **Drug of Choice (DOC):** *Pneumocystis jirovecii* pneumonia, *Nocardia*, and *Stenotrophomonas maltophilia*. * **Adverse Effects:** Megaloblastic anemia (reversed by Folinic acid), Stevens-Johnson Syndrome (due to SMZ), and hyperkalemia (TMP acts like a potassium-sparing diuretic in the distal tubule). * **Avoid in Pregnancy:** Risk of teratogenicity (antifolate effect) and kernicterus in the newborn (displacement of bilirubin from albumin by sulfonamides).

Question 928: Stavudine (Zerit) is prescribed to a client with human immunodeficiency virus seropositive. The nurse observes which of the following most closely while the client is taking the medication?

A. Orientation
B. Gag reflex
C. Appetite
D. Gait (Correct Answer)

Explanation: **Explanation:** **Stavudine (d4T)** is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in the management of HIV [2]. The correct answer is **Gait** because the most significant dose-limiting toxicity of Stavudine is **peripheral neuropathy** [3]. 1. **Why Gait is Correct:** Stavudine frequently causes distal symmetrical peripheral neuropathy, characterized by numbness, tingling, and pain in the feet and hands [3]. As the neuropathy progresses, it leads to sensory loss and muscle weakness, significantly affecting the patient's **gait** and balance. Monitoring the patient's walking pattern is a critical nursing intervention to detect early signs of neurotoxicity. 2. **Why Other Options are Incorrect:** * **Orientation:** While some antiretrovirals (like Efavirenz) cause CNS side effects, Stavudine is not primarily associated with altered consciousness or disorientation. * **Gag Reflex:** Stavudine does not affect the cranial nerves responsible for the gag reflex (CN IX, X). * **Appetite:** While NRTIs can cause GI upset, appetite is not the specific clinical parameter used to monitor for Stavudine's hallmark toxicity (neuropathy). **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Stavudine:** Remember the **"P"s**: **P**eripheral neuropathy and **P**ancreatitis [3]. * **Mechanism of Toxicity:** Stavudine (and Didanosine) inhibits **Mitochondrial DNA polymerase-gamma**, leading to mitochondrial dysfunction [1]. This is the underlying cause of both neuropathy and **Lactic Acidosis** (often accompanied by hepatic steatosis) [1]. * **Lipodystrophy:** Stavudine is strongly associated with **lipoatrophy** (loss of subcutaneous fat from the face and limbs), more so than other NRTIs [3]. * **Avoid Combination:** Stavudine should not be combined with **Zidovudine (AZT)** because they compete for the same intracellular phosphorylation pathway (antagonism) [3].

Question 929: What is the drug of choice for chlamydial cervicitis?

A. Tetracycline (Correct Answer)
B. Septran
C. Chloramphenicol
D. Erythromycin

Explanation: **Explanation:** **Chlamydial cervicitis** is caused by *Chlamydia trachomatis*, an obligate intracellular bacterium. Because it lacks a typical peptidoglycan cell wall and replicates within host cells, drugs that inhibit protein synthesis and achieve high intracellular concentrations are the mainstay of treatment. **Why Tetracycline is correct:** Tetracyclines (specifically **Doxycycline**) are highly effective against *Chlamydia* because they are lipid-soluble and easily penetrate host cells to reach the intracellular reticulate bodies. They inhibit protein synthesis by binding to the **30S ribosomal subunit**. While Azithromycin (a macrolide) is often used as a single-dose alternative in modern practice, Tetracyclines remain a classic "drug of choice" in standardized examinations for uncomplicated chlamydial infections. **Why other options are incorrect:** * **Septran (Co-trimoxazole):** While it has some activity against certain bacteria, it is not the standard of care for *Chlamydia* and has higher failure rates compared to tetracyclines. * **Chloramphenicol:** Although it has good intracellular penetration, its potential for serious bone marrow toxicity (e.g., Aplastic Anemia) makes it unsuitable for treating a common infection like cervicitis. * **Erythromycin:** This is an alternative treatment, particularly used in **pregnancy** where tetracyclines are contraindicated (due to fetal bone/teeth effects). However, it is less tolerated due to GI side effects and is not the primary drug of choice over tetracyclines in non-pregnant adults. **High-Yield Clinical Pearls for NEET-PG:** * **Doxycycline** (100 mg BID for 7 days) is the preferred tetracycline due to better compliance and fewer GI side effects. * **Azithromycin** (1g single dose) is the drug of choice if compliance is a concern or during pregnancy. * **Co-infection:** Always screen and treat for *Neisseria gonorrhoeae* (usually with Ceftriaxone) when treating Chlamydia, as co-infection is common. * **Lymhogranuloma Venereum (LGV):** Also caused by *Chlamydia*, requires a longer course (21 days) of Doxycycline.

Question 930: Which among the following is the drug of choice for Clostridium difficile-induced colitis?

A. Gentamicin
B. Ciprofloxacin
C. Metronidazole (Correct Answer)
D. Linezolid

Explanation: **Explanation:** **Clostridium difficile-induced colitis** (Pseudomembranous colitis) typically occurs due to the overgrowth of *C. difficile* following broad-spectrum antibiotic therapy (most commonly associated with Clindamycin, Fluoroquinolones, and Cephalosporins). **Why Metronidazole is correct:** Historically, **Metronidazole** (oral) has been the first-line drug of choice for mild-to-moderate cases of *C. difficile* infection (CDI) due to its efficacy, low cost, and narrow anaerobic spectrum. It works by forming toxic free radicals that disrupt the DNA of anaerobic bacteria. **Why the other options are incorrect:** * **Gentamicin:** An Aminoglycoside that is ineffective against anaerobes (it requires oxygen for bacterial uptake) and is a known risk factor for inducing CDI. * **Ciprofloxacin:** A Fluoroquinolone that is a common inciting agent for *C. difficile* overgrowth and has no role in its treatment. * **Linezolid:** An Oxazolidinone used primarily for Gram-positive infections like MRSA and VRE; it is not indicated for CDI. **High-Yield Clinical Pearls for NEET-PG:** 1. **Updated Guidelines:** While Metronidazole is the traditional answer for exams, recent **IDSA guidelines** now prefer **Oral Vancomycin** or **Fidaxomicin** as first-line for all episodes (including mild). However, if Vancomycin is unavailable or for mild cases in resource-limited settings, Metronidazole remains the standard answer. 2. **Route of Administration:** Vancomycin must be given **orally** for CDI; intravenous Vancomycin is ineffective as it does not reach the gut lumen. 3. **Fidaxomicin:** A macrocyclic antibiotic with minimal systemic absorption and a lower rate of recurrence compared to Vancomycin. 4. **Life-threatening/Fulminant CDI:** Treated with a combination of high-dose oral Vancomycin and IV Metronidazole.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free